<div id="readability-page-1"><div>(Alliance News) - AstraZeneca PLC on Monday said Imfinzi, in combination with chemotherapy, has been recommended for approval in the EU for the treatment of adult patients with resectable, early-stage and locally advanced gastric and gastroesophageal junction cancers.The Committee for Medicinal Products for Human Use of the European Medicines Agency based its positive opinion on event-free survival and overall survival data from the Matterhorn phase three trial, AstraZeneca said. The trial showed a 29% reduction in the risk of progression, recurrence or death and a 22% reduction in the risk of death for the Imfinzi regimen versus chemotherapy alone.&#34;The CHMP recommendation marks further progress toward our goal to offer novel approaches in early-stage cancers where there is the greatest chance for cure and brings us closer to providing the third perioperative Imfinzi-based regimen in the EU,&#34; said Susan Galbraith, executive vice president for Oncology Haematology R&amp;D at AstraZeneca. Imfinzi is approved in the US and other countries in the same indication based on the Matterhorn results. Regulatory applications are currently under review in Japan and other countries.In addition, the FTSE 100 listing said trading in its shares will begin on the New York Stock Exchange on Monday for the first time. AstraZeneca said the trading of its shares is now aligned across the NYSE, the London Stock Exchange and Nasdaq Stockholm under a harmonised listing structure. &#34;This will allow even more investors to participate in AstraZeneca's future,&#34; commented Chair Michel Demare. Last July, AstraZeneca pledged to invest USD50 billion in the US for medicines manufacturing and research &amp; development. In October, the Cambridge, England-based pharmaceuticals company struck a deal with the US government adopting a most-favoured-nation drug pricing model, designed to lower US costs to match the lowest in developed nations.AstraZeneca also reached an agreement with the US Department of Commerce to delay Section 232 tariffs for three years, enabling it to fully onshore medicines manufacturing so that all of its medicines sold in the US are made in the US. Shares in AstraZeneca were up 1.2% at 13,758.00 pence each in London on Monday morning. The wider FTSE 100 index was down 0.3%.By Jeremy Cutler, Alliance News reporterComments and questions to newsroom@alliancenews.comCopyright 2026 Alliance News Ltd. All Rights Reserved.</div></div>

阿斯利康獲得了歐盟對其藥物 Imfinzi 的積極推薦，該藥物與化療聯合用於治療早期胃癌。該推薦基於顯著的試驗結果，顯示出降低了疾病進展和死亡的風險。此外，阿斯利康的股票將在紐約證券交易所上市，統一其在主要交易所的上市。該公司承諾在美國製造和研發方面投資 500 億美元，並已達成協議以降低藥物成本和推遲關税，從而增強其在美國的運營能力

AstraZeneca hails Imfinzi green light ahead of New York trading debut

marketscreener

動態生物技術與基因組 ETF - Invesco

紐交所高增長板生物技術指數 ETF - First Trust

醫療業 ETF - SPDR

阿斯利康

生物科技 ETF - VanEck Vectors

醫藥突破 ETF - ALPS

基因改革 ETF - ARK

美國制藥 ETF - iShares

醫療業 ETF - Vanguard

標普全球醫療股指數 ETF - iShares

納斯達克生物科技指數 ETF - iShares Nasdaq

標普生物技術 ETF - SPDR

AstraZeneca PLC ADRhedged

2 倍做多納斯達克生物技術 ETF - ProShares

阿斯利康在紐約交易首次亮相前對 Imfinzi 獲得批准表示歡迎